FDA approves J&J and Grifols’ blood-stopping protein spray for surgical bleeds

Johnson & Johnson’s Ethicon unit has received a 510(k) clearance from the FDA for its Vistaseal applicators, which spray a biological sealant to stem moderate bleeding during open or laparoscopic surgical procedures. The airless spray products are the first fruit of a broad partnership between the device maker. and plasma-derived medicine manufacturer Grifols, which developed the human fibrin sealant for

Continue Reading

AZ looks to focus on early-stage cancer treatments

AstraZeneca is set to prioritize the treatment of early-stage cancers under the leadership of oncology research chief José Baselga, M.D., Ph.D. Talking to The Wall Street Journal, Baselga sketched out why he thinks splitting off from the congested pursuit of late-stage cancers will benefit AstraZeneca and patients. Under Baselga, AstraZeneca’s oncology group will initially test drugs in

Continue Reading

Drug Prices Will Soon Appear in Many TV Ads

The Trump administration for the first time will require pharmaceutical companies to include the price of prescription drugs in television advertisements if the cost exceeds $35 per month. Announced on Wednesday by Alex M. Azar II, the health and human services secretary, it is the most visible action the administration has taken so far to

Continue Reading

Gilead utilizes machine learning to find new NASH drugs

Gilead has been trying to construct a deeper NASH pipeline as prospects dim for its lead candidate in the space. Phase 3 data released in February showed the candidate, selonsertib, didn’t significantly outperform placebo in treating NASH patients who developed compensated cirrhosis because of severe liver scarring. ​While another trial evaluating the drug in less sick patients has

Continue Reading

BI broadens research pact with Vanderbilt University to develop GPCR drugs for brain disorders

Boehringer Ingelheim has been working to boost its research capabilities in central nervous system (CNS) disorders, making moves over the past year aimed specifically at adding compounds to its pipeline to address Alzheimer’s disease (AD), schizophrenia and depression. Now it’s teaming up with Vanderbilt University, located in Nashville to develop novel small molecules that modulate

Continue Reading